The local control of the pituitary by activin signaling and modulation

Open Neuroendocrinology Journal

Volumn 4, Issue SPEC. ISSUE 1, 2011, Pages 90-101

  Bilezikjian, Louise M ^a   Vale, Wylie W ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

Activin; Bone morphogenetic proteins; BPEs; Follistatin; FOXL2; FSHbeta; Gonadotrope; Gonadotropin; Inhibin; Lhbeta; Pituitary; Smad

Indexed keywords

ACTIVIN; ADENOSINE; BONE MORPHOGENETIC PROTEIN; CELL SURFACE RECEPTOR; CORTICOTROPIN; CYTOKINE; FOLLISTATIN; FOLLITROPIN; GHRELIN; GROWTH FACTOR; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; INHIBIN; LUTEINIZING HORMONE; NITRIC OXIDE; PROLACTIN; PROOPIOMELANOCORTIN; SMAD3 PROTEIN; SOMATOMEDIN; THYROTROPIN; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ACTH SECRETING CELL; ADENOHYPOPHYSIS; AUTOCRINE EFFECT; CELL TYPE; ENDOCRINE CELL; GONADOTROPIN SECRETING CELL; GROWTH HORMONE SECRETING CELL; HUMAN; HYPOPHYSIS; HYPOPHYSIS FUNCTION; HYPOTHALAMUS; NEUROMODULATION; PARACRINE SIGNALING; PATHOGENESIS; PRIORITY JOURNAL; PROLACTIN SECRETING CELL; REVIEW; TSH SECRETING CELL;

EID: 80555148815     PISSN: None     EISSN: 18765289     Source Type: Journal    
DOI: 10.2174/1876528901104010090     Document Type: Review

References (215)

1. Kaplan SA. The pituitary gland: a brief history. Pituitary 2007; 10(4): 323-325.
2. Charlton H. Hypothalamic control of anterior pituitary function: a history. J Neuroendocrinol 2008; 20(6): 641-646.
3. Denef C. Paracrinicity: the story of 30 years of cellular pituitary crosstalk. J Neuroendocrinol 2008; 20(1): 1-70.
4. Seilicovich A. Cell life and death in the anterior pituitary gland: role of oestrogens. J Neuroendocrinol 2010; 22(7): 758-764.
5. Nolan LA, Kavanagh E, Lightman SL, Levy A. Anterior pituitary cell population control: basal cell turnover and the effects of adrenalectomy and dexamethasone treatment. J Neuroendocrinol 1998; 10(3): 207-215.
6. Vankelecom H, Gremeaux L. Stem cells in the pituitary gland: A burgeoning field. Gen Comp Endocrinol 2010; 166(3): 478-488.
7. Gleiberman AS, Michurina T, Encinas JM, et al. Genetic approaches identify adult pituitary stem cells. Proc Natl Acad Sci USA 2008 29; 105(17): 6332-6337.
8. Garcia-Lavandeira M, Quereda V, Flores I, et al. A GRFa2/Prop1/stem (GPS) cell niche in the pituitary. PLoS One 2009; 4(3): e4815.
9. Kita A, Imayoshi I, Hojo M, et al. Hes1 and Hes5 control the progenitor pool, intermediate lobe specification, and posterior lobe formation in the pituitary development. Mol Endocrinol 2007; 21(6): 1458-1466.
10. Fauquier T, Rizzoti K, Dattani M, Lovell-Badge R, Robinson IC. SOX2-expressing progenitor cells generate all of the major cell types in the adult mouse pituitary gland. Proc Natl Acad Sci USA 2008 26; 105(8): 2907-2912.
11. Chen J, Gremeaux L, Fu Q, Liekens D, Van Laere S, Vankelecom H. Pituitary progenitor cells tracked down by side population dissection. Stem Cells 2009; 27(5): 1182-1195.
12. Horvath E, Coire CI, Kovacs K, Smyth HS. Folliculo-stellate cells of the human pituitary as adult stem cells: examples of their neoplastic potential. Ultrastruct Pathol 2010; 34(3): 133-139.
13. Massague J, Weis-Garcia F. Serine/threonine kinase receptors: mediators of transforming growth factor beta family signals. Cancer Surv 1996; 27: 41-64.
14. Wu MY, Hill CS. Tgf-beta superfamily signaling in embryonic development and homeostasis. Dev Cell 2009; 16(3): 329-343.
15. Xia Y, Schneyer AL. The biology of activin: recent advances in structure, regulation and function. J Endocrinol 2009; 202(1): 1-12.
16. Massague J. TGFbeta in Cancer. Cell 2008; 134(2): 215-230.
17. Bilezikjian LM, Blount A, Donaldson C, Vale W. Pituitary actions of ligands of the transforming growth factor-β family: activins and inhibin. Reproduction 2006; 132: 207-215.
18. Davis SW, Castinetti F, Carvalho LR, et al. Molecular mechanisms of pituitary organogenesis: In search of novel regulatory genes. Mol Cell Endocrinol 2010; 323(1): 4-19.
19. Zhu X, Wang J, Ju BG, Rosenfeld MG. Signaling and epigenetic regulation of pituitary development. Curr Opin Cell Biol 2007 Dec; 19(6): 605-611.
20. Danila DC, Inder WJ, Zhang X, et al. Activin effects on neoplastic proliferation of human pituitary tumors. J Clin Endocrinol Metab 2000; 85(3): 1009-1015.
21. Ezzat S. The role of hormones, growth factors and their receptors in pituitary tumorigenesis. Brain Pathol 2001; 11(3): 356-370.
22. Risbridger GP, Schmitt JF, Robertson DM. Activins and inhibins in endocrine and other tumors. Endocr Rev 2001; 22(6): 836-858.
23. Vale W, Hsueh A, Rivier C, Yu J. The inhibin/activin family of growth factors. In: Sporn MA, Roberts AB, Eds. Peptide Growth Factors and Their Receptors, Handbook of Experimental Pharmacology. Heidelberg: Springer-Verlag 1990; pp. 211-248.
24. Matzuk MM, Kumar TR, Shou W, et al. Transgenic models to study the roles of inhibins and activins in reproduction, oncogenesis, and development. Recent Prog Horm Res 1996; 51: 123-154; discussion 55-7.
25. Paez-Pereda M, Giacomini D, Refojo D, et al. Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk. Proc Natl Acad Sci USA 2003; 100(3): 1034-1039.
26. Alexander JM, Swearingen B, Tindall GT, Klibanski A. Human pituitary adenomas express endogenous inhibin subunit and follistatin messenger ribonucleic acids. J Clin Endocrinol Metab 1995; 80(1): 147-152.
27. Haddad G, Penabad JL, Bashey HM, et al. Expression of activin/inhibin subunit messenger ribonucleic acids by gonadotroph adenomas. J Clin Endocrinol Metab 1994; 79(5): 1399-1403.
28. Huang HJ, Wu JC, Su P, Zhirnov O, Miller WL. A novel role for bone morphogenetic proteins in the synthesis of follicle-stimulating hormone. Endocrinology 2001; 142(6): 2275-2283.
29. Faure MO, Nicol L, Fabre S, et al. BMP-4 inhibits folliclestimulating hormone secretion in ewe pituitary. J Endocrinol 2005; 186(1): 109-121.
30. Ho CC, Bernard DJ. Bone morphogenetic protein 2 signals via BMPR1A to regulate murine follicle-stimulating hormone beta subunit transcription. Biol Reprod 2009; 81(1): 133-141.
31. Nudi M, Ouimette JF, Drouin J. Bone morphogenic protein (Smad)-mediated repression of proopiomelanocortin transcription by interference with Pitx/Tpit activity. Mol Endocrinol 2005; 19(5): 1329-1342.
32. Labeur M, Paez-Pereda M, Haedo M, Arzt E, Stalla GK. Pituitary tumors: cell type-specific roles for BMP-4. Mol Cell Endocrinol 2010; 326(1-2): 85-88.
33. Otsuka F, Shimasaki S. A novel function of bone morphogenetic protein-15 in the pituitary: selective synthesis and secretion of FSH by gonadotropes. Endocrinology 2002; 143(12): 4938-4941.
34. Fitzpatrick SL, Sindoni DM, Shughrue PJ, Lane MV, Merchenthaler IJ, Frail DE. Expression of growth differentiation factor-9 messenger ribonucleic acid in ovarian and nonovarian rodent and human tissues. Endocrinology 1998; 139(5): 2571-2578.
35. Sarkar DK, Pastorcic M, De A, Engel M, Moses H, Ghasemzadeh MB. Role of transforming growth factor (TGF)-beta Type I and TGF-beta type II receptors in the TGF-beta1-regulated gene expression in pituitary prolactin-secreting lactotropes. Endocrinology 1998; 139(8): 3620-3628.
36. Hentges S, Boyadjieva N, Sarkar DK. Transforming growth factorbeta3 stimulates lactotrope cell growth by increasing basic fibroblast growth factor from folliculo-stellate cells. Endocrinology 2000; 141(3): 859-867.
37. Giacomini D, Paez-Pereda M, Stalla J, Stalla GK, Arzt E. Molecular interaction of BMP-4, TGF-beta, and estrogens in lactotrophs: impact on the PRL promoter. Mol Endocrinol 2009; 23(7): 1102-1114.
38. Lebrun JJ. Activin, TGF-beta and menin in pituitary tumorigenesis. Adv Exp Med Biol 2009; 668: 69-78.
39. Greenwald J, Vega M, Allendorph GP, Fischer W, Vale W, Choe S. A flexible activin can explain the membrane-dependent cooperative assembly of TGF-beta family receptors. Mol Cell 2004; 15(3): 485-489.
40. Thompson TB, Woodruff TK, Jardetzky TS. Structures of an ActRIIB: activin A complex reveal a novel binding mode for TGFbeta ligand: receptor interactions. EMBO J 2003; 22(7): 1555-1566.
41. Allendorph GP, Vale WW, Choe S. Structure of the ternary signaling complex of a TGF-beta superfamily member. Proc Natl Acad Sci USA 2006; 103(20): 7643-7648.
42. Miyazono K, Kamiya Y, Morikawa M. Bone morphogenetic protein receptors and signal transduction. J Biochem 2010; 147(1): 35-51.
43. Tsuchida K, Nakatani M, Yamakawa N, Hashimoto O, Hasegawa Y, Sugino H. Activin isoforms signal through type I receptor serine/threonine kinase ALK7. Mol Cell Endocrinol 2004; 220(1-2): 59-65.
44. Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, Ten-Dijke P. Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J 2002; 21(7): 1743-1753.
45. Oh SP, Seki T, Goss KA, et al. Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. Proc Natl Acad Sci USA 2000 Mar 14; 97(6): 2626-2631.
46. Massague J, Gomis RR. The logic of TGFbeta signaling. FEBS Lett 2006; 580(12): 2811-2820.
47. Schmierer B, Hill CS. TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol 2007 Nov 14.
48. Moustakas A, Heldin CH. The regulation of TGFbeta signal transduction. Development 2009; 136(22): 3699-3714.
49. Hahn SA, Schutte M, Hoque AT, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996; 271(5247): 350-353.
50. Bai S, Cao X. A nuclear antagonistic mechanism of inhibitory Smads in transforming growth factor-beta signaling. J Biol Chem 2002; 277(6): 4176-4182.
51. Hayashi H, Abdollah S, Qiu Y, et al. The MAD-related protein Smad7 associates with the TGFbeta receptor and functions as an antagonist of TGFβ signaling. Cell 1997; 89(7): 1165-1173.
52. Nakao A, Afrakhte M, Moren A, et al. Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature 1997; 389(6651): 631-635.
53. Imamura T, Takase M, Nishihara A, et al. Smad6 inhibits signalling by the TGF-beta superfamily. Nature 1997; 389(6651): 622-626.
54. Lebrun J-J, Takabe K, Chen Y, Vale WW. Roles of pathwayspecific and inhibitory Smads in activin receptor signaling. Mol Endocrinol 1999; 13(1): 15-23.
55. Massague J, Seoane J, Wotton D. Smad transcription factors. Genes Dev 2005; 19(23): 2783-2810.
56. Derynck R, Zhang Y, Feng XH. Smads: transcriptional activators of TGF-beta responses. Cell 1998; 95(6): 737-740.
57. Attisano L, Wrana JL. Smads as transcriptional co-modulators. Curr Opin Cell Biol 2000; 12(2): 235-243.
58. Ten-Dijke P, Miyazono K, Heldin CH. Signaling inputs converge on nuclear effectors in TGF-beta signaling. Trends Biochem Sci 2000; 25(2): 64-70.
59. Lo RS, Chen YG, Shi Y, Pavletich NP, Massague J. The L3 loop: a structural motif determining specific interactions between SMAD proteins and TGF-beta receptors. EMBO J 1998; 17(4): 996-1005.
60. Chacko BM, Qin B, Correia JJ, Lam SS, de Caestecker MP, Lin K. The L3 loop and C-terminal phosphorylation jointly define Smad protein trimerization. Nat Struct Biol 2001; 8(3): 248-253.
61. Matsuura I, Wang G, He D, Liu F. Identification and characterization of ERK MAP kinase phosphorylation sites in Smad3. Biochemistry 2005; 44(37): 12546-1253.
62. Kretzschmar M, Doody J, Timokhina I, Massague J. A mechanism of repression of TGFbeta/ Smad signaling by oncogenic Ras. Genes Dev 1999; 13(7): 804-816.
63. Kamaraju AK, Roberts AB. Role of Rho/ROCK and p38 MAP kinase pathways in transforming growth factor-beta-mediated Smad-dependent growth inhibition of human breast carcinoma cells in vivo. J Biol Chem 2005; 280(2): 1024-1036.
64. Matsuura I, Denissova NG, Wang G, He D, Long J, Liu F. Cyclindependent kinases regulate the antiproliferative function of Smads. Nature 2004; 430(6996): 226-231.
65. Li P, Wang D, Lucas J, et al. Atrial natriuretic peptide inhibits transforming growth factor beta-induced Smad signaling and myofibroblast transformation in mouse cardiac fibroblasts. Circ Res. 2008; 102(2): 185-192.
66. Shi Y, Wang YF, Jayaraman L, Yang H, Massague J, Pavletich NP. Crystal structure of a Smad MH1 domain bound to DNA: insights on DNA binding in TGF-beta signaling. Cell 1998; 94(5): 585-594.
67. Chen X, Weisberg E, Fridmacher V, Watanabe M, Naco G, Whitman M. Smad4 and FAST-1 in the assembly of activinresponsive actor. Nature 1997; 389(6646): 85-89.
68. Liu F, Pouponnot C, Massague J. Dual role of the Smad4/DPC4 tumor suppressor in TGF beta-inducible transcriptional complexes. Genes Dev 1997; 11(23): 3157-3167.
69. Zhou S, Zawel L, Lengauer C, Kinzler KW, Vogelstein B. Characterization of human FAST-1, a TGF beta and activin signal transducer. Mol Cell Biol 1998; 2(1): 121-127.
70. Dunn NR, Vincent SD, Oxburgh L, Robertson EJ, Bikoff EK. Combinatorial activities of Smad2 and Smad3 regulate mesoderm formation and patterning in the mouse embryo. Development 2004; 131(8): 1717-1728.
71. Zhu Y, Richardson JA, Parada LF, Graff JM. Smad3 mutant mice develop metastatic colorectal cancer. Cell 1998; 94(6): 703-7014.
72. Waldrip WR, Bikoff EK, Hoodless PA, Wrana JL, Robertson EJ. Smad2 signaling in extraembryonic tissues determines anteriorposterior polarity of the early mouse embryo. Cell 1998; 92(6): 797-808.
73. Ohnishi H, Miyata T, Yasuda H, et al. Distinct roles of Smad2-, Smad3-, and ERK-dependent pathways in transforming growth factor-beta1 regulation of pancreatic stellate cellular functions. J Biol Chem 2004; 279(10): 8873-8878.
74. Brown KA, Pietenpol JA, Moses HL. A tale of two proteins: differential roles and regulation of Smad2 and Smad3 in TGF-beta signaling. J Cell Biochem 2007; 101(1): 9-33.
75. Kang JS, Liu C, Derynck R. New regulatory mechanisms of TGFbeta receptor function. Trends Cell Biol 2009; 19(8): 385-394.
76. De Kretser DM, Robertson DM, Risbridger GP, et al. Inhibin and related peptides. Prog Endocrinol 1988: 13-23.
77. Mather JP, Moore A, Li RH. Activins, inhibins, and follistatins: further thoughts on a growing family of regulators. Proc Soc Exp Biol Med 1997; 215(3): 209-222.
78. Woodruff TK. Regulation of cellular and system function by ctivin. Biochem Pharmacol 1998; 55(7): 953-963.
79. Massague J. TGF-β signal transduction. Annu Rev Biochem 1998; 67: 753-791.
80. Matzuk MM, Finegold MJ, Mather JP, Krummen L, Lu H, Bradley A. Development of cancer cachexia-like syndrome and adrenal tumors in inhibin-deficient mice. Proc Natl Acad Sci USA 1994; 91(19): 8817-8821.
81. Stenvers KL, Findlay JK. Inhibins: from reproductive hormones to umor suppressors. Trends Endocrinol Metab 2010; 21(3): 174-180.
82. Farnworth PG, Harrison CA, Leembruggen P, et al. Inhibin binding sites and proteins in pituitary, gonadal, adrenal and bone cells. Mol Cell Endocrinol 2001; 180(1-2): 63-71.
83. Harrison CA, Farnworth PG, Chan KL, et al. Identification of specific inhibin A-binding proteins on mouse Leydig (TM3) and sertoli (TM4) cell lines. Endocrinology 2001; 142(4): 1393-1402.
84. Draper LB, Matzuk MM, Roberts VJ, et al. Identification of an inhibin receptor in gonadal tumors from inhibin alpha-subunit knockout mice. J Biol Chem 1998; 273(1): 398-403.
85. Chong H, Pangas SA, Bernard DJ, et al. Structure and expression of a membrane component of the inhibin receptor system [see comments]. Endocrinology 2000; 141(7): 2600-2607.
86. Lewis KA, Gray PC, Blount AL, et al. Betaglycan binds inhibin and can mediate functional antagonism of activin signaling. Nature 2000; 404(6776): 411-414.
87. MacConell LA, Leal A, Vale W. The distribution of betaglycan protein and mRNA in rat brain, pituitary and gonads: Implications for a role in inhibin-mediated reproductive functions. Endocrinology 2002; 143(3): 1066-1075.
88. Chapman SC, Woodruff TK. Betaglycan localization in the female rat pituitary: implications for the regulation of follicle-stimulating hormone by inhibin. Endocrinology 2003; 144(12): 5640-5649.
89. Wiater E, Lewis KA, Donaldson C, Vaughan J, Bilezikjian L, Vale W. Endogenous Betaglycan Is Essential for High Potency Inhibin Antagonism in Gonadotropes. Mol Endocrinol 2009; 23(7): 1033-1042.
90. Escalona RM, Stenvers KL, Farnworth PG, Findlay JK, Ooi GT. Reducing betaglycan expression by RNA interference (RNAi) attenuates inhibin bioactivity in LbetaT2 gonadotropes. Mol Cell Endocrinol 2009; 307(1-2): 149-156.
91. Wiater E, Harrison CA, Lewis KA, Gray PC, Vale WW. Identification of distinct inhibin and transforming growth factor β- binding sites on betaglycan: functional separation of betaglycan coreceptor actions. J Biol Chem 2006; 281: 17011-17022.
92. Lopez-Casillas F, Cheifetz S, Doody J, Andres JL, Lane WS, Massague J. Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-beta receptor system. Cell 1991; 67(4): 785-795.
93. Farnworth PG, Stanton PG, Wang Y, Escalona R, Findlay JK, Ooi GT. Inhibins differentially antagonize activin and bone morphogenetic protein action in a mouse adrenocortical cell line. Endocrinology 2006; 147(7): 3462-3471.
94. Wiater E, Vale W. Inhibin is an antagonist of bone morphogenetic protein signaling. J Bio Chem 2003; 278(10): 7934-7941.
95. Ethier JF, Farnworth PG, Findlay JK, Ooi GT. Transforming Growth Factor- β Modulates Inhibin A Bioactivity in the LβT2 Gonadotrope Cell Line by Competing for Binding to Betaglycan. Mol Endocrinol 2002; 16(12): 2754-2763.
96. Looyenga BD, Wiater E, Vale W, Hammer GD. Inhibin-A antagonizes TGFbeta2 signaling by down-regulating cell surface expression of the TGFbeta coreceptor betaglycan. Mol Endocrinol 2010; 24(3): 608-620.
97. Farnworth PG, Wang Y, Leembruggen P, et al. Rodent adrenocortical cells display high affinity binding sites and proteins for inhibin A, and express components required for autocrine signalling by activins and bone morphogenetic proteins. J Endocrinol 2006; 188(3): 451-465.
98. Stenvers KL, Tursky ML, Harder KW, et al. Heart and liver defects and reduced transforming growth factor beta2 sensitivity in transforming growth factor beta type III receptor-deficient embryos. Mol Cell Biol 2003; 23(12): 4371-4385.
99. Roberts VJ, Peto CA, Vale W, Sawchenko PE. Inhibin/activin subunits are costored with FSH and LH in secretory granules of the rat anterior pituitary gland. Neuroendocrinology 1992; 56: 214-224.
100. Bilezikjian LM, Leal AMO, Blount A, Corrigan AZ, Turnbull AV, Vale W. Rat anterior pituitary folliculo-stellate cells are targets of interleukin-1β and a major source of intrapituitary follistatin. Endocrinology 2003; 144(2): 732-740.
101. Bilezikjian LM, Vaughan JM, Vale WW. Characterization and the regulation of inhibin/activin subunit proteins of cultured rat anterior pituitary cells. Endocrinology 1993; 133: 2545-2553.
102. Liu ZH, Shintani Y, Wakatsuki M, et al. Regulation of immunoreactive activin-A secretion from cultured rat anterior pituitary cells. Endocr J 1996; 43(1): 39-44.
103. Carroll RS, Corrigan AZ, Gharib SD, Vale WW, Chin WW. Inhibin, activin and follistatin: regulation of follicle-stimulating hormone messenger ribonucleic acid levels. Mol Endocrinol 1989; 3: 1969-1976.
104. Corrigan AZ, Bilezikjian LM, Carroll RS, et al. Evidence for an autocrine role of activin B within rat anterior pituitary cultures. Endocrinology 1991; 128: 1682-1684.
105. DePaolo LV, Bald LN, Fendly BM. Passive immunoneutralization with a monoclonal antibody reveals a role for endogenous activin- B in mediating FSH hypersecretion during estrus and following ovariectomy of hypophysectomized, pituitary-grafted rats. Endocrinology 1992; 130(3): 1741-1743.
106. Weiss J, Harris PE, Halvorson LM, Crowley JWF, Jameson JL. Dynamic regulation of follicle-stimulating hormone-β messenger ribonucleic acid levels by activin and gonadotropin-releasing hormone in perifused rat pituitary cells. Endocrinology 1992; 131(3): 1403-148.
107. Cameron VA, Nishimura E, Mathews LS, Lewis KA, Sawchenko PE, Vale WW. Hybridization histochemical localization of activin receptor subtypes in rat brain, pituitary, ovary and testis. Endocrinology 1994; 134(2): 799-808.
108. Wilson ME, Handa RJ. Activin subunit, follistatin, and activin receptor gene expression in the prepubertal female rat pituitary. Biol Reprod 1998; 59(2): 278-283.
109. Kitaoka M, Kojima I, Ogata E. Activin-A: a modulator of multiple types of anterior pituitary cells. Biochem Biophys Res Commun 1988; 157: 48-54.
110. Bilezikjian LM, Corrigan AZ, Vale WW. Activin-A modulates growth hormone secretion from cultures of rat anterior pituitary cells. Endocrinology 1990; 126: 2369-2376.
111. Bilezikjian LM, Blount AL, Campen CA, Gonzalez-Manchon C, Vale WW. Activin-A inhibits proopiomelanocortin messenger RNA accumulation and adrenocorticotropin secretion of AtT20 cells. Mol Endocrinol 1991; 5: 1389-1395.
112. Bilezikjian LM, Vale WW. Local extragonadal roles of activins. Trends Endocrinol Metab 1992; 3: 218-223.
113. Billestrup N, Gonzalez-Manchon C, Potter E, Vale WW. Inhibition of somatotroph growth and GH biosynthesis by activin in vitro. Mol Endocrinol 1990; 4: 356-362.
114. Coss D, Thackray VG, Deng CX, Mellon PL. Activin regulates luteinizing hormone beta-subunit gene expression through Smadbinding and homeobox elements. Mol Endocrinol 2005; 19(10): 2610-2623.
115. Woodruff TK, Mather JP. Inhibin, activin and the female reproductive axis. Annu Rev Physiol 1995; 57: 219-244.
116. Chang H, Brown CW, Matzuk MM. Genetic analysis of the mammalian transforming growth factor-beta superfamily. Endocr Rev 2002; 23(6): 787-823.
117. Kumar TR, Agno J, Janovick JA, Conn PM, Matzuk MM. Regulation of FSHβ and GnRH receptor gene expression in activin receptor II knockout male mice. Mol Cell Endocrinol 2003; 212(1-2): 19-27.
118. Vassalli A, Matzuk MM, Gardner HAR, Lee KF, Jaenisch R. Activin/Inhibin beta b subunit gene disruption leads to defects in eyelid development and female reproduction. Gene Dev 1994; 8(4): 414-427.
119. Suszko MI, Balkin DM, Chen Y, Woodruff TK. Smad3 mediates activin-induced transcription of follicle-stimulating hormone betasubunit gene. Mol Endocrinol 2005; 19(7): 1849-1858.
120. Pernasetti F, Vasilyev VV, Rosenberg SB, et al. Cell-specific transcriptional regulation of follicle-stimulating hormone-beta by activin and gonadotropin-releasing hormone in the LbetaT2 pituitary gonadotrope cell model. Endocrinology 2001; 142(6): 2284-2295.
121. Thackray VG, Mellon PL, Coss D. Hormones in synergy: regulation of the pituitary gonadotropin genes. Mol Cell Endocrinol 2010; 314(2): 192-203.
122. Bernard DJ, Fortin J, Wang Y, Lamba P. Mechanisms of FSH synthesis: what we know, what we don't, and why you should care. Fertil Steril 2010; 93(8): 2465-2485.
123. Gregory SJ, Lacza CT, Detz AA, Xu S, Petrillo LA, Kaiser UB. Synergy between activin A and gonadotropin-releasing hormone in transcriptional activation of the rat follicle-stimulating hormonebeta gene. Mol Endocrinol 2005; 19(1): 237-254.
124. Coss D, Hand CM, Yaphockun KK, Ely HA, Mellon PL. P38 mitogen-activated protein kinase is critical for synergistic induction of the FSH(beta) gene by gonadotropin-releasing hormone and activin through augmentation of c-Fos induction and Smad phosphorylation. Mol Endocrinol 2007; 21(12): 3071-3086.
125. Lamba P, Santos MM, Philips DP, Bernard DJ. Acute regulation of murine follicle-stimulating hormone beta subunit transcription by activin A. J Mol Endocrinol 2006; 36(1): 201-220.
126. Burger LL, Haisenleder DJ, Dalkin AC, Marshall JC. Regulation of gonadotropin subunit gene transcription. J Mol Endocrinol 2004; 33(3): 559-584.
127. Burger LL, Haisenleder DJ, Wotton GM, Aylor KW, Dalkin AC, Marshall JC. The regulation of FSHbeta transcription by gonadal steroids: testosterone and estradiol modulation of the activin intracellular signaling pathway. Am J Physiol Endocrinol Metab 2007; 293(1): E277-E285.
128. Antenos M, Zhu J, Jetly NM, Woodruff TK. An activin/furin regulatory loop modulates the processing and secretion of inhibin alpha- and betaB-subunit dimers in pituitary gonadotrope cells. J Biol Chem 2008; 283(48): 33059-33068.
129. Bilezikjian LM, Blount A, Leal AMO, Donaldson C, Fischer W, Vale W. Autocrine/paracrine regulation of pituitary function by activin, inhibin and follistatin. Mol Cell Endocrinol 2004; 225: 29-36.
130. Bilezikjian LM, Corrigan AZ, Blount AL, Chen Y, Vale WW. Regulation and actions of Smad7 in the modulation of activin, inhibin and TGFβ signaling in anterior pituitary cells. Endocrinology 2001; 142(3): 1065-1072.
131. Alexander JM, Bikkal HA, Zervas NT, Laws ER, Jr., Klibanski A. Tumor-specific expression and alternate splicing of messenger ribonucleic acid encoding activin/transforming growth factor-beta receptors in human pituitary adenomas. J Clin Endocrinol Metab 1996; 81(2): 783-790.
132. Takeda M, Otsuka F, Suzuki J, et al. Involvement of activin/BMP system in development of human pituitary gonadotropinomas and nonfunctioning adenomas. Biochem Biophys Res Commun 2003; 306(4): 812-818.
133. Uccella S, La Rosa S, Genasetti A, Capella C. Localization of inhibin/activin subunits in normal pituitary and in pituitary adenomas. Pituitary 2000; 3(3): 131-139.
134. Danila DC, Zhang X, Zhou Y, Haidar JN, Klibanski A. Overexpression of wild-type activin receptor alk4-1 restores activin antiproliferative effects in human pituitary tumor cells. J Clin Endocrinol Metab 2002; 87(10): 4741-4746.
135. Shimonaka M, Inouye S, Shimasaki S, Ling N. Follistatin binds to both activin and inhibin through the common beta-subunit. Endocrinology 1991; 128: 3313-3315.
136. Inouye S, Guo Y, DePaolo L, Shimonaka M, Ling N, Shimasaki S. Recombinant expression of human follistatin with 315 and 288 amino acids: chemical and biological comparison with native porcine follistatin. Endocrinology 1991; 129: 815-822.
137. Michel U, Farnworth P, Findlay JK. Follistatins: more than folliclestimulating hormone suppressing proteins. Mol Cell Endocrinol 1993; 91: 1-11.
138. DePaolo LV. Inhibins, activins, and follistatins: the saga continues. Proc Soc Exp Biol Med 1997; 214(4): 328-339.
139. Phillips DJ, deKretser DM. Follistatin: A multifunctional regulatory protein. Front Neuroendocrinol 1998; 19(4): 287-322.
140. Welt C, Sidis Y, Keutmann H, Schneyer A. Activins, inhibins, and follistatins: from endocrinology to signaling. A paradigm for the new millennium. Exp Biol Med (Maywood) 2002; 227(9): 724-752.
141. Fischer WH, Park M, Donaldson C, et al. Residues in the Cterminal region of activin-A determine specificity for follistatin and type II receptor binding. J Endocrinol 2003; 176(1): 61-68.
142. Keutmann HT, Schneyer AL, Sidis Y. The role of follistatin domains in follistatin biological action. Mol Endocrinol 2004; 18(1): 228-240.
143. Thompson TB, Lerch TF, Cook RW, Woodruff TK, Jardetzky TS. The structure of the follistatin: activin complex reveals antagonism of both type I and type II receptor binding. Dev Cell 2005; 9(4): 535-543.
144. Harrington AE, Morris-Triggs SA, Ruotolo BT, Robinson CV, Ohnuma S, Hyvonen M. Structural basis for the inhibition of activin signalling by follistatin. EMBO J 2006; 25(5): 1035-1045.
145. Harrison CA, Chan KL, Robertson DM. Activin-A binds follistatin and type II receptors through overlapping binding sites: generation of mutants with isolated binding activities. Endocrinology 2006; 147(6): 2744-2753.
146. Harrison C, Wiater E, Gray P, Greenwald J, Choe S, Vale W. Modulation of activin and BMP signaling. Mol Cell Endocrinol 2004; 225: 19-24.
147. DePaolo LV, Bicsak TA, Erickson GF, Shimasaki S, Ling N. Follistatin and activin: a potential intrinsic regulatory system within diverse tissues. Proc Soc Exp Biol Med 1991; 198(1): 500-512.
148. Balemans W, Van Hul W. Extracellular regulation of BMP signaling in vertebrates: a cocktail of modulators. Dev Biol 2002; 250(2): 231-250.
149. Canalis E, Economides AN, Gazzerro E. Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr Rev 2003; 24(2): 218-235.
150. Krneta J, Kroll J, Alves F, et al. Dissociation of angiogenesis and tumorigenesis in follistatin- and activin-expressing tumors. Cancer Res 2006; 66(11): 5686-5695.
151. Ogino H, Yano S, Kakiuchi S, et al. Follistatin suppresses the production of experimental multiple-organ metastasis by small cell lung cancer cells in natural killer cell-depleted SCID mice. Clin Cancer Res 2008; 14(3): 660-667.
152. Matzuk MM, Lu N, Vogel H, Sellheyer K, Roop DR, Bradley A. Multiple defects and perinatal death in mice deficient in follistatin. Nature 1995; 374(6520): 360-363.
153. Guo Q, Kumar TR, Woodruff T, Hadsell LA, DeMayo FJ, Matzuk MM. Overexpression of mouse follistatin causes reproductive defects in transgenic mice. Mol Endocrinol 1998; 12(1): 96-106.
154. Lin SY, Morrison JR, Matzuk MM, de Kretser DM. Spermatogenesis does not require the local production of follistatin. Reproduction 2006; 132(4): 601-605.
155. Jorgez CJ, Klysik M, Jamin SP, Behringer RR, Matzuk MM. Granulosa cell-specific inactivation of follistatin causes female fertility defects. Mol Endocrinol 2004; 18(4): 953-967.
156. Shimasaki S, Koga M, Esch F, et al. Porcine follistatin gene structure supports two forms of ature follistatin produced by alternative splicing. Biochem Biophys Res Commun 1988; 152: 717-723.
157. Michel U, Albiston A, Findlay JK. Rat Follistatin - Gonadal and Extragonadal Expression and Evidence for Alternative Splicing. Biochem Biophys Res Commun 1990; 173(1): 401-407.
158. Sugino K, Kurosawa N, Nakamura T, et al. Molecular heterogeneity of follistatin, an Activin-Binding protein - higher affinity of the Carboxyl-Terminal truncated forms for heparin sulfate proteoglycans on the ovarian granulosa cell. J Biol Chem 1993; 268(21): 15579-15587.
159. Kimura F, Sidis Y, Bonomi L, Xia Y, Schneyer A. The follistatin- 288 isoform alone is sufficient for survival but not for normal fertility in mice. Endocrinology 2010; 151(3): 1310-1319.
160. Lin SY, Craythorn RG, O'Connor AE, et al. Female infertility and disrupted angiogenesis are actions of specific follistatin isoforms. Mol Endocrinol 2008; 22(2): 415-429.
161. Kaiser UB, Lee BL, Carroll RS, Unabia G, Chin WW, Childs GV. Follistatin gene expression in the pituitary: localization in gonadotropes and folliculostellate cells in diestrous rats. Endocrinology 1992; 130: 3048-3056.
162. Lan-Lee B, Unabia G, Childs G. Expression of follistatin mRNA by somatotropes and mammotropes early in the rat estrous cycle. J Histochem Cytochem 1993; 41: 955-960.
163. Gospadarowicz D, Lau K. Pituitary follicular cells secrete both vascular endothelial growth factor and follistatin. Biochem Biophys Res Commun 1989; 165: 292-298.
164. Kogawa K, Nakamura T, Sugino K, Takio K, Titani K, Sugino H. Activin-binding protein is present in pituitary. Endocrinology 1991; 128: 1434-1440.
165. Farnworth PG, Thean E, Robertson DM, Schwartz J. Ovine anterior pituitary production of follistatin in vitro. Endocrinology 1995; 136(10): 4397-4406.
166. Bilezikjian LM, Corrigan AZ, Vaughan JM, Vale WW. Activin-A regulates follistatin secretion from cultured rat anterior pituitary cells. Endocrinology 1993; 133: 2554-2560.
167. Haisenleder DJ, Aylor KW, Burger LL, Dalkin AC, Marshall JC. Stimulation of FSHbeta transcription by blockade of endogenous pituitary follistatin production: Efficacy of adenoviral- elivered antisense RNA in the rat. Endocrine 2006; 29(3): 399-404.
168. Bauer-Dantoin AC, Weiss J, Jameson JL. Gonadotropin-releasing hormone regulation of pituitary follistatin gene expression during the primary follicle-stimulating hormone surge. Endocrinology 1996; 137(5): 1634-1639.
169. Besecke LM, Guendner MJ, Sluss PA, et al. Pituitary follistatin regulates activin-mediated production of follicle-stimulating hormone during the rat estrous cycle. Endocrinology 1997; 138(7): 2841-2848.
170. Halvorson LM, Weiss J, Bauer-Dantoin AC, Jameson JL. Dynamic regulation of pituitary follistatin messenger ribonucleic acids during the rat estrous cycle. Endocrinology 1994; 134(3): 1247-1253.
171. Prendergast KA, Burger LL, Aylor KW, Haisenleder DJ, Dalkin AC, Marshall JC. Pituitary follistatin gene expression in female rats: evidence that inhibin regulates transcription. Biol Reprod 2004; 70(2): 364-370.
172. Kaiser UB, Chin WW. Regulation of follistatin messenger ribonucleic acid levels in the rat pituitary. J Clin Invest 1993; 91: 2523-2531.
173. Dalkin AC, Haisenleder DJ, Gilrain JT, Aylor K, Yasin M, Marshall JC. Regulation of pituitary follistatin and inhibin/activin subunit messenger ribonucleic acids (mRNAs) in male and female rats: evidence for inhibin regulation of follistatin mRNA in females. Endocrinology 1998; 139(6): 2818-2823.
174. Bohnsack BL, Szabo M, Kilen SM, Tam DHY, Schwartz NB. Follistatin suppresses steroid-enhanced follicle-stimulating hormone release in vitro in rats. Biol Reprod 2000; 62(3): 636-641.
175. Leal AMO, Blount AL, Donaldson C, Bilezikjian LM, Vale WW. Regulation of follicle-stimulating hormone secretion by the interactions of activinA, dexamethasone and testosterone in anterior pituitary cell cultures of male rats. Neuroendocrinology 2003; 77(5): 298-304.
176. Kirk SE, Dalkin AC, Yasin M, Haisenleder DJ, Marshall JC. Gonadotropin-releasing hormone pulse frequency regulates expression of pituitary follistatin messenger ribonucleic acid: a mechanism for differential gonadotrope function. Endocrinology 1994; 135(3): 876-880.
177. DePaolo LV, Mercado M, Guo Y, Ling N. Increased follistatin (activin-binding protein) gene expression in rat anterior pituitary tissue after ovariectomy may be mediated by pituitary activin. Endocrinology 1993; 132: 2221-2228.
178. Besecke LM, Guendner MJ, Schneyer AL, Bauer-Dantoin AC, Jameson JL, Weiss J. Gonadotropin-releasing hormone regulates follicle-stimulating hormone- β gene expression through an activin/follistatin autocrine or paracrine loop. Endocrinology 1996; 137(9): 3667-3673.
179. Kawakami S, Fujii Y, Okada Y, Winters SJ. Paracrine regulation of FSH by follistatin in folliculostellate cell-enriched primate pituitary cell cultures. Endocrinology 2002; 143(6): 2250-2258.
180. Katayama T, Shiota K, Sugino H, Takahashi M. Paracrine effect of folliculo-stellate cells on the growth factor-like action of activin A in anterior pituitary cultures. Endocrinol Jpn 1992; 39(3): 289-297.
181. Katayama T, Nakashima M, Kyan H, Murakami N, Kuroda H. A role of pituitary adenylate cyclase activating polypeptide (PACAP) as a regulator of paracrine interactions between folliculo-stellate cells and gonadotropes through the control of activin-follistatin interactions. J Vet Med Sci 2000; 62(7): 731-736.
182. Bilezikjian LM, Corrigan AZ, Blount AL, Vale WW. Pituitary follistatin and inhibin subunit mRNA levels are differentially regulated by local and hormonal factors. Endocrinology 1996; 137(10): 4277-4284.
183. Blount A, Vaughan J, Vale W, Bilezikjian LM. A SMAD-binding element in intron 1 participates in activin-dependent regulation of the follistatin gene. J Biol Chem 2008; 283(11): 7016-7026.
184. Miyanaga K, Shimasaki S. Structural and functional characterization of the rat follistatin (activin-binding protein) gene promoter. Mol Cell Endocrinol 1993; 92: 99-109.
185. de Groot E, Veltmaat J, Caricasole A, Defize L, van den Eijndenvan Raaij A. Cloning and analysis of the mouse follistatin promoter. Mol Biol Rep 2000; 27(3): 129-139.
186. Willert J, Epping M, Pollack JR, Brown PO, Nusse R. A transcriptional response to Wnt protein in human embryonic carcinoma cells. BMC Dev Biol 2002; 2(1): 8.
187. Li H, Malbon CC, Wang HY. Gene profiling of Frizzled-1 and Frizzled-2 signaling: expression of G-protein-coupled receptor chimeras in mouse F9 teratocarcinoma embryonal cells. Mol Pharmacol. 2004; 65(1): 45-55.
188. Takeda M, Otsuka F, Otani H, et al. Effects of peroxisome proliferator-activated receptor activation on gonadotropin transcription and cell mitosis induced by bone morphogenetic proteins in mouse gonadotrope LbetaT2 cells. J Endocrinol 2007 Jul; 194(1): 87-99.
189. Kihara S, Yamamoto H, Ohba T, Shimasaki S, Okamura H. Activation of follistatin promoter by GnRH in LbetaT2 gonadotroph cells. Endocr J 2006; 53(2): 225-235.
190. Winters SJ, Ghooray D, Fujii Y, Moore JP, Jr., Nevitt JR, Kakar SS. Transcriptional regulation of follistatin expression by GnRH in mouse gonadotroph cell lines: evidence for a role for cAMP signaling. Mol Cell Endocrinol 2007; 271(1-2): 45-54.
191. Mutiara S, Kanasaki H, Oride A, et al. Follistatin gene expression by gonadotropin-releasing hormone: a role for cyclic AMP and mitogen-activated protein kinase signaling pathways in clonal gonadotroph LbetaT2 cells. Mol Cell Endocrinol 2009; 307(1-2): 125-132.
192. Winters SJ, Dalkin AC, Tsujii T. Evidence that pituitary adenylate cyclase activating polypeptide suppresses follicle-stimulating hormone-beta messenger ribonucleic acid levels by stimulating follistatin gene transcription. Endocrinology 1997; 138(10): 4324-4329.
193. Blount AL, Schmidt K, Justice NJ, Vale WW, Fischer WH, Bilezikjian LM. Foxl2 and Smad3 coordinately regulate follistatin gene transcription. J Biol Chem 2009; 284: 7631-7645.
194. Bartholin L, Maguer-Satta V, Hayette S, et al. FLRG, an activinbinding protein, is a new target of TGFbeta transcription activation through Smad proteins. Oncogene 2001; 20(39): 5409-5419.
195. Bartholin L, Maguer-Satta V, Hayette S, et al. Transcription activation of FLRG and follistatin by activin A, through Smad proteins, participates in a negative feedback loop to modulate activin A function. Oncogene 2002; 21(14): 2227-2235.
196. Kioussi C, O'Connell S, St-Onge L, et al. Pax6 is essential for establishing ventral-dorsal cell boundaries in pituitary gland development. Proc Natl Acad Sci USA 1999; 96(25): 14378-14382.
197. Treier M, Gleiberman AS, O'Connell SM, et al. Multistep signaling requirements for pituitary organogenesis in vivo. Genes Dev 1998; 12(11): 1691-1704.
198. Ellsworth BS, Egashira N, Haller JL, et al. FOXL2 in the pituitary: molecular, genetic, and developmental analysis. Mol Endocrinol 2006; 20(11): 2796-2805.
199. Ellsworth BS, Burns AT, Escudero KW, Duval DL, Nelson SE, Clay CM. The gonadotropin releasing hormone (GnRH) receptor activating sequence (GRAS) is a composite regulatory element that interacts with multiple classes of transcription factors including Smads, AP-1 and a forkhead DNA binding protein. Mol Cell Endocrinol 2003; 206(1-2): 93-111.
200. Lamba P, Fortin J, Tran S, Wang Y, Bernard DJ. A novel role for the forkhead transcription factor FOXL2 in activin A-regulated follicle-stimulating hormone beta subunit transcription. Mol Endocrinol. 2009 Jul; 23(7): 1001-1013.
201. Corpuz PS, Lindaman LL, Mellon PL, Coss D. FoxL2 Is required for activin induction of the mouse and human follicle-stimulating hormone beta-subunit genes. Mol Endocrinol 2010; 24(5): 1037-1051.
202. Schmidt D, Ovitt CE, Anlag K, et al. The murine winged-helix transcription factor Foxl2 is required for granulosa cell differentiation and ovary maintenance. Development 2004; 131(4): 933-942.
203. Uda M, Ottolenghi C, Crisponi L, et al. Foxl2 disruption causes mouse ovarian failure by pervasive blockage of follicle development. Hum Mol Genet 2004; 13(11): 1171-1181.
204. Uhlenhaut NH, Jakob S, Anlag K, et al. Somatic sex reprogramming of adult ovaries to testes by FOXL2 ablation. Cell 2009; 139(6): 1130-1142.
205. Wijchers PJ, Burbach JP, Smidt MP. In control of biology: of mice, men and Foxes. Biochem J 2006; 397(2): 233-246.
206. Carlsson P, Mahlapuu M. Forkhead transcription factors: key players in development and metabolism. Dev Biol 2002; 250(1): 1-23.
207. Prueitt RL, Zinn AR. A fork in the road to fertility. Nat Genet 2001; 27(2): 132-134.
208. Cocquet J, Pailhoux E, Jaubert F, et al. Evolution and expression of FOXL2. J Med Genet 2002; 39(12): 916-921.
209. Crisponi L, Deiana M, Loi A, et al. The putative forkhead transcription factor FOXL2 is mutated in blepharophimosis/-ptosis/epicanthus inversus syndrome. Nat Genet 2001; 27(2): 159-166.
210. De Baere E, Dixon MJ, Small KW, et al. Spectrum of FOXL2 gene mutations in blepharophimosis-ptosis-epicanthus inversus (BPES) families demonstrates a genotype--phenotype correlation. Hum Mol Genet 2001; 10(15): 1591-1600.
211. Pannetier M, Fabre S, Batista F, et al. FOXL2 activates P450 aromatase gene transcription: towards a better characterization of the early steps of mammalian ovarian development. J Mol Endocrinol 2006; 36(3): 399-413.
212. Wang DS, Kobayashi T, Zhou LY, et al. Foxl2 up-regulates aromatase gene transcription in a female-specific manner by binding to the promoter as well as interacting with ad4 binding protein/steroidogenic factor 1. Mol Endocrinol 2007; 21(3): 712-725.
213. Pisarska MD, Bae J, Klein C, Hsueh AJ. Forkhead l2 is expressed in the ovary and represses the promoter activity of the steroidogenic acute regulatory gene. Endocrinology 2004; 145(7): 3424-3433.
214. Shah SP, Kobel M, Senz J, et al. Mutation of FOXL2 in granulosacell tumors of the ovary. N Engl J Med 2009; 360(26): 2719-2729.
215. st Annual Meeting of the Endocrine Society 2000; pp 3-244.